Latest Breaking News On - Drug controller general - Page 1 : comparemela.com

DCGI Orders Withdrawal of AstraZeneca's Cancer Drug Olaparib for Some Treatments

The Drug Controller General of India (DCGI) has asked drug regulators in all states and Union territories to withdraw AstraZeneca s anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy.

Wockhardt Q4 results: Reports net loss of ₹177 crore; antibiotic products show progress

Wockhardt Limited reports reduced net loss, plans to launch new antibiotics, files patents, and raises funds for growth.

Don't pop that pill daily: Doctors red-flag proton pump inhibitors used to treat acid reflux, heartburns

AstraZeneca: India's drug regulator orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects |

DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was

DCGI orders withdrawal of cancer drug Olaparib for certain treatments

The communication stated that the firm presented the clinical evidence for the withdrawal of indication of Olaparib tablets.